CD38 and plasma cell myeloma: For our German-Speaking-Myeloma-Multicenter-Group (GMMG), this posed a surprising hurdle in defining the rationale of our CONCEPT trial (EudraCT 2016-000432-17), adding anti-CD38 treatment for symptomatic high-risk patients.